| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794305 | Ophthalmology | 2017 | 10 Pages |
Abstract
The BRIGHTER study results confirmed the long-term efficacy and safety profile of PRN dosing driven by individualized VA stabilization criteria using ranibizumab 0.5 mg in patients with BRVO. Addition of laser did not lead to better functional outcomes or lower treatment need. The safety results were consistent with the well-established safety profile of ranibizumab.
Keywords
CSFTBRVOPRNSAEcentral reading centerETDRSBCVAstandard deviationBranch retinal vein occlusionOctbest-corrected visual acuityOptical coherence tomographyVisual acuityearly treatment diabetic retinopathy studycentral subfield thicknesspro re nataadverse eventSerious adverse eventconfidence intervalCRCLeast squares
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ramin MD, PhD, Sebastian M. MD, PhD, Francesco MD, Heinrich MD, Margarita MD, Elizabeth PhD, Ayan MS, Andreas PhD, Ian FRCOphth, BRIGHTER Study Group BRIGHTER Study Group,